Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bavarian Nordic Signs Contract To Deliver Imvamune
Bavarian Nordic has signed a contract with the military of an undisclosed EU country for the delivery of a small order for Imvamune. The vaccines will be delivered
Bavarian Nordic has signed a contract with the military of an undisclosed EU country for the delivery of a small order for Imvamune. The vaccines will be delivered
The FDA has granted Orphan Drug Designation to Advanced Life Sciences’ Restanza (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Advanced
BioCryst has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing
HUYA Bioscience International has entered into a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The agreement with GIBH is expected
NiKem Research has received, from the Italian Ministry of Health, GLP certification of its bioanalysis facilities to further extend its drug discovery service capabilities. With this certification NiKem
The FDA has approved the design of a single, pivotal, phase III clinical trial evaluating BioVex’s lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous
GENova Biotherapeutics (GENova) has gained access to distribution channels for its drug targets through a recently-signed deal with Bridge BioResearch. Through a recent collaboration deal, the two companies
Basilea Pharmaceutica’s (Basilea) anti-infective compounds ceftobiprole, isavuconazole and the novel antibiotic BAL30072’s data were presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San
Cell Therapeutics (CTI) has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for
Novartis has reported results from phase III trial showing QAB149 (indacaterol) significantly improves lung function and provides reduction in breathlessness compared to tiotropium, a current treatment option. QAB149